Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 7/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.36 |
| ▸ | RORC | P51449 | 5/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13108646 | 0.91 | RORC (0.38) | ARSLC22A12RORCS1PR3ALDH1A1 | |
| SCHEMBL13108643 | 0.90 | RORC (0.39) | ARSLC22A12RORCALDH1A1LMNA | |
| SCHEMBL13108632 | 0.88 | RORC (0.40) | ARSLC22A12RORCALDH1A1LMNA | |
| SCHEMBL27777714 | 0.88 | RORC (0.40) | ARSLC22A12RORCALDH1A1LMNA | |
| SCHEMBL13108636 | 0.87 | AR (0.38) | ARSLC22A12RORCALDH1A1LMNA | |
| SCHEMBL3021119 | 0.87 | S1PR3 (0.39) | ARSLC22A12RORCS1PR3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3026428 | 0.86 | S1PR3 (0.39) | ARSLC22A12RORCS1PR3ALDH1A1 | |
| SCHEMBL13108623 | 0.86 | AR (0.40) | ARSLC22A12RORCALDH1A1LMNA | |
| SCHEMBL27756886 | 0.86 | AR (0.40) | ARSLC22A12RORCALDH1A1LMNA | |
| SCHEMBL12345120 | 0.85 | RORC (0.40) | ARSLC22A12RORCALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049104-B1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | GLAXOSMITHKLINE LLC (US) | 2012-09-19 | — | — | EP | disclosed |
| US-7816395-B2 | Pyrrolidinone anilines as progesterone receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816395-B2 | Pyrrolidinone anilines as progesterone receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-10-19 | — | — | US | disclosed |
| US-20100210706-A1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100210706-A1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-08-19 | — | — | US | disclosed |
| WO-2008021796-A2 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080039517-A1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | GLAXOSMITHKLINE LLC | 2008-02-14 | — | — | US | disclosed |
| US-20080039517-A1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | GLAXOSMITHKLINE LLC | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039517-A1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | PGR, PGRMC2, PGRMC1 | AR 14/4885SLC22A12 2181/4885RORC 266/4885 |
| US-20100210706-A1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | PGR, PGRMC2, PGRMC1 | AR 14/4885SLC22A12 2181/4885RORC 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.